Advanced Solid Tumor research hub

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

This study is testing a new drug, NXP800, for people with advanced cancers. It aims to find a safe dose and see how well it works, especially for certain types of ovarian cancer that have a specific genetic change called ARID1a mutation.